Order Article Reprints

Gentile I, Scotto R, Scirocco MM, Di Brizzi F, Cuccurullo F, Silvitelli M, Ametrano L, Alfè FA, Pietroluongo D, Irace I, et al. Efficacy of Molnupiravir in Reducing the Risk of Severe Outcomes in Patients with SARS-CoV-2 Infection: A Real-Life Full-Matched Case–Control Study (SAVALO Study). Microorganisms. 2025; 13(3):669. https://doi.org/10.3390/microorganisms13030669

Gentile, Ivan, Riccardo Scotto, Maria Michela Scirocco, Francesco Di Brizzi, Federica Cuccurullo, Maria Silvitelli, Luigi Ametrano, Francesco Antimo Alfè, Daria Pietroluongo, Irene Irace, and et al. 2025. "Efficacy of Molnupiravir in Reducing the Risk of Severe Outcomes in Patients with SARS-CoV-2 Infection: A Real-Life Full-Matched Case–Control Study (SAVALO Study)" Microorganisms 13, no. 3: 669. https://doi.org/10.3390/microorganisms13030669

Gentile, I., Scotto, R., Scirocco, M. M., Di Brizzi, F., Cuccurullo, F., Silvitelli, M., Ametrano, L., Alfè, F. A., Pietroluongo, D., Irace, I., Chiariello, M., De Felice, N., Severino, S., Viceconte, G., Schiano Moriello, N., Maraolo, A. E., Buonomo, A. R., Giaccone, A., & on behalf of Federico II COVID Team. (2025). Efficacy of Molnupiravir in Reducing the Risk of Severe Outcomes in Patients with SARS-CoV-2 Infection: A Real-Life Full-Matched Case–Control Study (SAVALO Study). Microorganisms, 13(3), 669. https://doi.org/10.3390/microorganisms13030669